Breast Cancer

Xichun Hu, MD, PhD, discusses a study of tibremciclib plus fulvestrant in HR+/HER2– advanced breast cancer following progression on endocrine therapy.

Bria-IMT plus an immune checkpoint inhibitor completely resolved a breast cancer metastasis and shrunk an eye-bulging orbital lesion in 1 patient.

Panelists discuss how addressing unmet needs in patient selection, resistance mechanisms, and long-term outcomes can enhance the efficacy of antibody-drug conjugates in breast cancer treatment.

Oleg Gluz, MD, highlights the feasibility of de-escalated neoadjuvant therapy plus trastuzumab and pertuzumab in patients with HR+/HER2+ breast cancer.

The sBLA for trastuzumab deruxtecan in hormone receptor–positive, HER2-low or -ultralow breast cancer has been accepted for priority review by the FDA.

Cynthia X. Ma, MD, PhD, discusses current unmet needs associated with the use of CDK4/6 inhibitors in the treatment of breast cancer.

Breast cancer experts highlight early-phase and real-world studies of interest from the 2024 ESMO Congress.

The risk of lymphedema was comparable for hypofractionated radiation therapy and normofractionated radiation therapy in early breast cancer.

Bora Lim, MD, discusses the significance of the FDA approval of adjuvant ribociclib for patients with HR-positive, HER2-negative breast cancer.

Ann H. Partridge, MD, MPH, discusses unique challenges associated with very young patients who have ER+/node-positive breast cancer.

Panelists discuss how, despite the investigational status of agents like patritumab deruxtecan (HER3-DXd) and datopotamab deruxtecan (Dato-DXd), it’s crucial for community oncologists to be aware of the treatment-related adverse effects (TRAEs) associated with these therapies and to consider effective management strategies as reported in clinical trials.

A statistically significant difference in PFS was not observed between chemotherapy backbone and HRD status in first-line TNBC.

Virginia Kaklamani, MD, discusses the optimal role for adjuvant ribociclib alongside endocrine therapy in early-stage HR+/HER2– breast cancer.

Panelists discuss how ongoing clinical trials of investigational antibody-drug conjugates (ADCs) are advancing treatment options for breast cancer, particularly in patients with active brain metastases and advanced disease.

Patients with HR-positive breast cancer who conceived during a break from endocrine therapy found breastfeeding feasible and safe.

No significant improvement in OS was observed with Dato-DXd vs chemotherapy in pretreated HR-positive, HER2-low or -negative metastatic breast cancer.

Bora Lim, MD, discusses the FDA approval of adjuvant ribociclib plus an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer.

Adjuvant ribociclib receives FDA approval for HR+ breast cancer, AMG 193 elicits responses in MTAP-deleted solid tumors, and more this week from OncLive.

Pelareorep plus paclitaxel improved overall survival in endocrine-refractory, hormone receptor–positive/HER2-negative advanced breast cancer.

Elacestrant plus abemaciclib demonstrated clinical activity and manageable safety in pretreated ER+/HER2– metastatic breast cancer.

Panelists discuss how the multidisciplinary team plays a crucial role in managing treatment-resistant adverse effects for patients receiving antibody-drug conjugates, emphasizing collaboration among oncologists, pharmacists, nurses, and specialists to optimize patient care and ensure comprehensive support.

Panelists discuss how management and monitoring for pneumonitis and cardiotoxicity in trastuzumab deruxtecan (T-DXd) is similar to trastuzumab emtansine (T-DM1), while also emphasizing the need for awareness of adverse effects such as peripheral neuropathy, thrombocytopenia, and hepatotoxicity, along with strategies for their management and when to consider therapy modifications.

The FDA approved adjuvant ribociclib plus an aromatase inhibitor in patients with HR-positive, HER2-negative early breast cancer.

Yuan Yuan, MD, PhD, discusses radiation therapy approaches across various of breast cancer subtypes.

Frontline abemaciclib plus ET demonstrated a superior ORR vs chemotherapy in HR+/HER2– advanced breast cancer with aggressive disease characteristics.

Adding ribociclib to a NSAI in the adjuvant setting prolonged invasive and distant disease-free survival in HR-positive, HER2-negative early breast cancer.

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

Yuan Yuan, MD, PhD, discusses key research evaluating adjuvant CDK4/6 inhibition in breast cancer.

T-DXd improved time to deterioration for pain and other subscores, with no decline in overall QOL in HER2 low/ultralow breast cancer.

Neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, improved overall survival in triple-negative breast cancer.